Title: Cytochrome P450 2S1 is reduced by NADPH-cytochrome P450 reductase.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20110601
Title: Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1.
Journal: Molecular pharmacology 20100901
Title: Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).
Journal: Molecular cancer therapeutics 20090501
Title: The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.
Journal: Cancer research 20090201
Title: Gene therapy approaches to enhance bioreductive drug treatment.
Journal: The British journal of radiology 20081001
Title: Evaluation of the antiangiogenic potential of AQ4N.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080301
Title: Bioreductive drugs: from concept to clinic.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain)) 20070801
Title: AQ4, an antitumor anthracenedione, inhibits endothelial cell proliferation and vascular endothelial growth factor secretion: implications for the therapy of ocular neovascular disorders.
Journal: European journal of pharmacology 20070730
Title: Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070401
Title: Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry.
Journal: Rapid communications in mass spectrometry : RCM 20070101
Title: Tumor hypoxia in cancer therapy.
Journal: Methods in enzymology 20070101
Title: Hypoxia: targeting the tumour.
Journal: Anti-cancer agents in medicinal chemistry 20060701
Title: Radiation sensitization with redox modulators: a promising approach.
Journal: International journal of radiation oncology, biology, physics 20060201
Title: A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.
Journal: The journal of gene medicine 20050701
Title: The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.
Journal: British journal of cancer 20010801
Title: A preclinical pharmacokinetic study of the bioreductive drug AQ4N.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20010401
Title: Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.
Journal: British journal of cancer 20000601
Title: Hejmadi MV, et al. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Br J Cancer. 1996 Feb;73(4):499-505.
Title: Manley E Jr, et al. Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone. J Pharmacol Exp Ther. 2013 Feb;344(2):368-77.
Title: Williams KJ, et al. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts. Mol Cancer Ther. 2009 Dec;8(12):3266-75.
